SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC Cancer Drug, Vandetanib Tied to Substantial Toxicity

November 30, 2010 | 
1 min read
Bloomberg -- AstraZeneca Plc’s experimental thyroid cancer treatment may cause “substantial toxicity,” according to U.S. regulators weighing whether the product should be approved for sale.
Clinical research Phase III
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Crumpled paper balls fly into a miniature bucket, the concept of searching for new ideas
Lung cancer
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Obesity
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
May 12, 2025
 · 
2 min read
 · 
Tristan Manalac
istock/ArtemisDiana
PARTNERED
Where AI Adds Real Value in Clinical Development
May 12, 2025
 · 
7 min read
 · 
BioSpace Insights
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
 · 
1 min read
 · 
Lori Ellis